Therapeutic strategies for cardiogenic shock, 2006

被引:7
作者
Ellis T.C. [1 ]
Lev E. [1 ]
Yazbek N.F. [1 ]
Kleiman N.S. [1 ]
机构
[1] Department of Cardiology, Methodist Debakey Heart Center, Houston, TX 77030
关键词
Acute Myocardial Infarction; Systemic Inflammatory Response Syndrome; Cardiogenic Shock; Abciximab; Levosimendan;
D O I
10.1007/s11936-006-0028-4
中图分类号
学科分类号
摘要
Cardiogenic shock, a devastating consequence of acute myocardial infarction, is associated with extremely high mortality. Treatment strategies should focus on prompt reperfusion and hemodynamic support. The primary approach for therapy is emergent angiography and revascularization using percutaneous coronary intervention or coronary artery bypass surgery, with the assistance of intra-aortic balloon pump counterpulsation. Several adjunctive pharmacologic agents, particularly inotropic drugs and vasopressors, are also helpful for hemodynamic support. However, these agents have not been shown to provide a survival benefit, and their use is primarily based on clinical experience. Since our last publication, several important advances have been made in the understanding and treatment of cardiogenic shock. Recent evidence suggests that a systemic inflammatory response, including the upregulation of inducible nitric oxide synthase, complement activation, and an inflammatory cytokine cascade, play a role in the development of cardiogenic shock. Newer therapeutic strategies, including C5 inhibitors and nitric oxide synthase inhibitors, are being combined with traditional strategies, such as inotropic agents, vasopressors, and circulatory assist, to treat cardiogenic shock. Copyright © 2006 by Current Science Inc.
引用
收藏
页码:79 / 94
页数:15
相关论文
共 77 条
[1]  
Holmes Jr. D.R., Bates E.R., Kleiman N.S., Et al., Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience, J Am Coll Cardiol, 26, pp. 68-674, (1995)
[2]  
Hochman J.S., Sleeper L.A., Webb J.G., Et al., Early revascularization in acute myocardial infarction complicated by cardiogenic shock, N Engl J Med, 341, pp. 625-634, (1999)
[3]  
Killip III T., Kimball J.T., Treatment of myocardial infarction in a coronary care unit. A two-year experience with 250 patients, Am J Cardiol, 20, pp. 457-464, (1967)
[4]  
Babaev A., Frederick P.D., Pasta D., Et al., Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock, JAMA, 294, pp. 448-454, (2005)
[5]  
Theroux P., Armstrong P.W., Mahaffey K.W., Et al., Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the COMMA trial, Eur Heart J, 26, pp. 1964-1970, (2005)
[6]  
Potapov E.V., Hennig F., Wagner F.D., Et al., Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure, Eur J Cardiothorac Surg, 27, pp. 899-905, (2005)
[7]  
Webb J.G., Sleeper L.A., Buller C.E., Et al., Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: A report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock?, J Am Coll Cardiol, 36, 3 SUPPL. A, pp. 1084-1090, (2000)
[8]  
Page D.L., Caulfield J.B., Kastor J.A., Et al., Myocardial changes associated with cardiogenic shock, N Engl J Med, 285, pp. 133-137, (1971)
[9]  
Alonso D.R., Scheidt S., Post M., Killip T., Pathophysiology of cardiogenic shock Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations, Circulation, 48, pp. 588-596, (1973)
[10]  
Holmes Jr. D.R., Berger P.B., Hochman J.S., Et al., Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation, Circulation, 100, pp. 2067-2073, (1999)